Ambient Sound Investments acquires 26% of Celure

Investment group Ambient Sound Investments acquired 26% of Celecure by investing € 1.6 million into the company.

Celecure Ltd. (www.celecure.com)
Celecure is an Estonian capital based company focusing on preclinical development of drugs against cancer and other diseases based on its novel angiogenesis inhibition technology and Entrybody(TM) platform. Entrybody(TM) consists of antibodies that are cell-permeable and block intracellular proteins that advance the diseases.

Celecure is developing a novel angiogenesis inhibitor SB101. Celecure has proven that the angiogenesis Inhibitor SB101 has better effect in animal tests than Avastin – the only drug now available able to block the angiogenesis inside the tumor. In addition, SB101 does not cause toxic side-effects.

Celecure has filed for national patents in the European Union, USA, Canada, Australia, Japan, China and India and has already started collaboration talks with international pharmaceutical companies.

Ambient Sound Investments (www.asi.ee)
Ambient Sound Investments is an investment company of four Estonian co-founders of Skype, using its assets to fund budding international technology enterprises. ASI is mostly focusing on Eastern Europe and Russia, searching companies that are developing new technologies or based thereon to be added to its investment portfolio.